S trong inwardly rectifying potassium channels (a family of channels termed K IR ) influence the membrane potential and contractile state of several kinds of vascular smooth muscle and contribute to vasodilator responses to modestly increased extracellular potassium ion concentrations ([K ϩ ] o Ͻ15 mmol/L) in vitro. [1] [2] [3] [4] Such responses could be physiologically or pathologically important because elevated [K ϩ ] o occurs in exercising muscle and during myocardial or cerebral ischemia. K ϩ has also been implicated as an endothelium-derived hyperpolarizing factor (EDHF) in some 5 but not all 6 blood vessels. Electrophysiological, molecular biological, and gene knockout experiments have shown that one member of the K IR channel family, K IR 2.1, is needed for K IR currents and for K ϩ -induced vasodilation in rat cerebral arteries in vitro, effects that are blocked by Ba 2ϩ concentrations Ͻ100 mol/L. 7, 8 It is not known, however, whether K IR channels control human resistance vasculature under physiological conditions in vivo, and the present study addresses this. Ba 2ϩ has been proposed as a probe of the functional role of K IR channels, 2 and concentrations of Ba 2ϩ Ͻ100 mol/L are relatively specific for these channels. 9 Higher concentrations of Ba 2ϩ (100 to Ͼ1000 mol/L) are needed to block non-K IR potassium channels, including HERG (an inwardly rectifying potassium channel present in human hippocampus and distinct from K IR 2.1), 10 ATP-sensitive K-channels, 11 Ca 2ϩ -activated K-channels, 12 and K V channels. 13 Soluble barium salts are rapidly absorbed from the intestinal tract, and Ba 2ϩ is toxic in systemically active doses. Acute toxic effects of Ba 2ϩ , which include hypertension, are consistent with block of K IR . 14 Human studies identified a no-observed adverse-effect dose of 0.21 mg barium/kg body wt per day. 15, 16 These data were used by the US Environmental Protection Agency to calculate a chronic oral reference dose of 0.07 mg/kg per day. 17, 18 In one study, human volunteers were given up to 10 mg/L in drinking water daily for up to 10 weeks. There were no clinically significant adverse events. 16 We calculated that brachial artery infusion of BaCl 2 could achieve a local Ba 2ϩ concentration of 30 to 50 mol/L in plasma of the infused forearm without causing systemic toxicity. 3 Brachial artery infusion of ouabain was therefore used in some experiments to produce unilateral regional block of Na ϩ /K ϩ ATPase. 20 -22 Experiments with vasodilators (verapamil and nitroprusside) and vasoconstrictors (norepinephrine) that act by mechanisms distinct from K IR and the Na ϩ /K ϩ pump were used to control for possible nonspecific effects.
Methods

Human Studies
The St Thomas' Hospital Research Ethics Committee approved all the studies, and subjects gave written informed consent. Studies were performed in healthy normotensive (arterial pressure, 116Ϯ4/ 70Ϯ2 mm Hg; meanϮSEM), normocholesterolemic (mean serum cholesterol, 3.6Ϯ0.2 mmol/L) men (mean age, 33Ϯ2 years) who were taking no medication. Studies were performed in the morning in a temperature-controlled room (24Ϯ1°C). The left brachial artery was cannulated with a 27-gauge stainless steel needle (Cooper's Needleworks) after local anesthesia (Ͻ1 mL 1% lidocaine). Isotonic saline (140 mmol/L sodium chloride ) with or without dissolved drugs was infused at 1 mL/min. BaCl 2 was administered through a syringe filter (Acrodisc, 0.2 m, Pall Corporation). Subjects rested supine for 30 minutes, and saline was infused for 12 minutes before measuring baseline flow. Blood flow (milliliter per minute per deciliter of forearm volume) was measured simultaneously in both arms by venous occlusion plethysmography 23 with the use of electrically calibrated strain gauges. 24 During measurements, the hands were excluded from the circulation by inflation of wrist cuffs to 180 mm Hg. Upper arm cuffs were intermittently inflated to 40 mm Hg, and the mean of the last 5 readings of each infusion period was used for analysis.
Plasma Ba 2؉ Analysis
In preliminary dose-ranging studies, 19-gauge plastic cannulas were inserted into the medial antecubital veins draining each forearm. Venous blood (10 mL) was sampled at baseline, during the final 30 seconds of the infusion of BaCl 2 , and 1 hour after infusion for determination of plasma Ba 2ϩ concentration. Samples were immediately centrifuged (1600g for 5 minutes), and plasma was stored at Ϫ18°C in Ba 2ϩ -free tubes. Samples were analyzed in duplicate in the Trace Element Unit, Southampton Hospital, with the use of inductively coupled plasma (ICP) mass spectrometry (Perkin Elmer-Sciex Elan 5000 ICP mass spectrometer), detection limit of 10 nmol/L, with a 0.5-mL plasma sample. Routine serum chemistries including creatinine, electrolytes, and liver function tests, in addition to Ba 2ϩ concentration, were measured at baseline and 1 week after BaCl 2 infusion.
In preliminary dose-finding experiments, cumulative infusions of intra-arterial BaCl 2 (0.25 to 2.0 mol/min, each for 4 minutes) were administered. From these pilot studies, a dose of BaCl 2 of 4 mol/min for up to 6 minutes was chosen for the following protocols.
Effects of BaCl 2 and Ouabain on Basal Forearm Blood Flow
After measuring basal forearm blood flow as above, BaCl 2 (4 mol/min) was infused into the brachial artery for 6 minutes and blood flow was measured in both arms (nϭ8). In 6 of these subjects, plasma Ba 2ϩ determinations were made as above. In 10 separate experiments, ouabain (2.7 nmol/min) was infused for 15 minutes and blood flows were measured as described elsewhere. 21 Ouabain was continued for a further 3 minutes, coinfused with BaCl 2 (4 mol/min).
Effects of Ba 2؉ (With or Without Ouabain) on Forearm Responses to K ؉ or Verapamil
After measuring basal forearm blood flow, cumulative doses (0.05, 0.1, 0.2 mmol/min, nϭ8) of KCl were infused into the brachial artery, each dose for 3 minutes. Venous blood samples (10 mL) were taken from both arms during the final 30 seconds for determination of plasma K ϩ concentration. In separate experiments (nϭ8), KCl (0.2 mmol/min) was infused for 3 minutes followed by saline for 15 minutes, during which blood flow returned to baseline. BaCl 2 (4 mol/min) was then infused for 6 minutes: alone for 3 minutes and during a second 3-minute infusion of KCl (0.2 mmol/min). In control experiments, after blood flow was measured at baseline, verapamil (80 nmol/min) was infused with saline followed sequentially by saline alone, BaCl 2 alone, and verapamil with BaCl 2 (nϭ7).
In further separate experiments (nϭ6), blood flow was measured as before at baseline and during KCl (0.2 mmol/min), followed by a 15-minute saline recovery period. Ouabain and BaCl 2 were infused as described above and continued during a final 3-minute KCl infusion (0.2 mmol/min).
Lack of Effect of Norepinephrine on Forearm Blood Flow Response to KCl
Baseline blood flow was measured, followed by KCl infusion for 3 minutes (0.2 mmol/min, nϭ5). Saline was then infused alone for a 15-minute recovery period, followed by norepinephrine (240 pmol/min), initially alone for 3 minutes, and then continued throughout a second 3-minute KCl infusion.
Lack of Effect of BaC1 2 Plus Ouabain on Forearm Blood Flow Response to Nitroprusside
Baseline blood flow was measured during saline, followed by nitroprusside (3.3 nmol/min or 33 nmol/min for 3 minutes, nϭ4). Saline was then infused for a 15-minute recovery period, followed by sequential cumulative additions of ouabain (2.7 nmol/min), BaCl 2 (4 mol/min), and nitroprusside (3.3 or 33 nmol/min), with the same timings used as above.
Materials and Drugs
Drugs were obtained from Baxter Healthcare (saline); David Bull Laboratories (sodium nitroprusside); Antigen Pharmaceuticals (KCl, lidocaine); Abbott Laboratories (norepinephrine); BDH Laboratories (BaCl 2 10% wt/vol); Jenapharm (ouabain); and Baker Norton (verapamil).
Statistical Analysis
Data are presented as meanϮSEM. Vasodilator responses were calculated as increases of blood flow (mL/min per deciliter of forearm tissue) above the immediately preceding baseline. 25, 26 Vasoconstrictor responses were calculated as percentage decrease of blood flow ratio of the infused to noninfused arm. 27, 28 Differences between means were evaluated for statistical significance by means of Student's paired t test (2-sided) or repeated-measures ANOVA, as appropriate. Differences were considered significant at a level of PϽ0.05.
Results
Neither arterial blood pressure nor forearm blood flow in the noninfused arm changed significantly during any study, consistent with lack of systemic hemodynamic effects of the infused agents at the doses used. BaCl 2 caused no acute ECG changes and had no significant effect on serum electrolytes and liver function tests measured 1 week after the infusion.
Effects of Ba 2؉ and Ouabain on Basal Flow
In pilot experiments, cumulative, rising doses of BaCl 2 (0.25, 0.5, 1.0, and 2.0 mol/min, nϭ6), each infused through the brachial artery for 4 minutes, had no significant effect on baseline flow (percent change in baseline flow, Ϫ10Ϯ10%, Ϫ9Ϯ7%, Ϫ2Ϯ14%, and 1Ϯ15%, respectively, PϭNS). Plasma Ba 2ϩ concentration at baseline (ie, before BaCl 2 infusion) was 0.28Ϯ0.04 mol/L and during the final 30 seconds of infusion (at 2.0 mol/min) was 22Ϯ3.4 mol/L and 1.7Ϯ0.9 mol/L, in the infused and noninfused arms respectively.
BaCl 2 (4 mol/min for 6 minutes) reduced baseline blood flow by 24Ϯ4% (nϭ8, PϽ0.001, Figure 1) . Plasma Ba 2ϩ concentration in venous blood draining the infused arm was 50Ϯ8 mol/L during the final 30 seconds of the infusion (Table 1) .
Ouabain (2.7 nmol/min) reduced baseline blood flow by 10Ϯ2% (nϭ10, PϽ0.05) and coinfusion of BaCl 2 with ouabain reduced baseline flow by 28Ϯ3% (nϭ10, PϽ0.0005 compared with the effect of ouabain alone, Figure 1 ).
Effect of K ؉ on Forearm Blood Flow
All subjects reported warmth and tingling in the infused arm during KCl infusion, and in preliminary experiments discomfort limited the maximum dose that was consistently tolerated to 0. Figure 3B and Table 4 ).
Effects of
Responses to KCl were measured before and during vasoconstriction with norepinephrine. Norepinephrine (240 pmol/min) reduced baseline blood flow by 24Ϯ2% (nϭ5, PϽ0.05). KCl (0.2 mmol/min) increased forearm blood flow by 3.01Ϯ0.45 mL/min per deciliter forearm over baseline when infused alone and by 3.79Ϯ0.64 mL/min per deciliter of forearm when coinfused with norepinephrine (PϭNS, Figure 3C ).
Vasodilator responses to nitroprusside were measured in the presence and absence of Ba 2ϩ and ouabain (Table 4) . Nitroprusside Figure 3D ).
Discussion
Ba
2؉ as a Probe of K IR Function in Human Forearm Resistance Vasculature
Electrophysiological and molecular studies have established the presence of K IR 2.1 channels in isolated vascular smooth muscle. 7, 8, 23 However, K IR channels are blocked by Ca 2ϩ and Mg 2ϩ , 9 each present in millimolar concentrations in extracellular fluid, and other signal transduction mechanisms could overwhelm any contribution to basal tone from K IR in vivo. Ba 2ϩ can be used to probe the functional role of K IR channels. 2 We investigated the possible role of K IR channels in human resistance vasculature in vivo by using brachial artery administration of BaCl 2 with bilateral measurement of forearm blood flow. Doses were selected to produce concentrations that are pharmacologically active locally in the infused forearm but not systemically, and no significant effects on blood pressure or on blood flow in the contralateral (noninfused) forearm were observed. The dose of Ba 2ϩ administered during each study was less than the daily reference dose, and no adverse effects were observed. The mean concentration of Ba 2ϩ measured in plasma from the infused arm was 50Ϯ0.8 mol/L, sufficient to block K IR channels. [2] [3] [4] [7] [8] [9] Ouabain and other drugs were similarly administered through the brachial artery in doses that are not active systemically 20 -22 and produced no change in blood flow in the noninfused arm.
A major concern with this approach is the possibility that Ba 2ϩ and ouabain, in the doses studied, could have effects in addition to those on K IR and Na ϩ /K ϩ ATPase. Bilateral measurement of forearm blood flow coupled with brachial artery administration of subsystemically active doses circumvents confounding from drug actions on the central nervous system or heart, which cause bilateral changes in forearm blood flow. 26 Thus, central effects of ouabain resulting in increased vascular resistance cannot explain its unilateral effects on the infused forearm. Similarly, actions of Ba 2ϩ on the heart or central nervous system cannot explain its unilateral effects in the infused arm. Concentrations of Ba 2ϩ in the range of 100 to Ͼ1000 mol/L are needed to block other potassium channels, 10 -13 which have not been implicated in K ϩ -induced vasodilation and are unlikely to underlie the effect of Ba 2ϩ described here. However, it is not possible to exclude completely some other property of Ba 2ϩ in the physiological milieu of the human forearm. In particular, physicochemical properties shared with Ca 2ϩ raise the theoretical possibility that Ba 2ϩ could exert some of the effects we observed by influencing [ 2, 4 Consequently, unequivocal evidence of the presence and function of K IR 2.1 channels in arterial smooth muscle in vitro 4, 7, 8 does not, of itself, prove the functional importance of these channels under in vivo conditions. The modest vasoconstriction caused in the forearm by ouabain (10Ϯ2% reduction in basal blood flow, consistent with previous work 20 -22 ) and greater effect of Ba 2ϩ , demonstrated here for the first time, are consistent with tonic activity of K ϩ on Na ϩ /K ϩ ATPase and, more effectively, on K IR -channels in vascular smooth muscle in forearm resistance vessels in vivo. Tonic K ϩ -related vasodilation could have been underestimated by the inhibition observed (24Ϯ4% by Ba 2ϩ alone, 28Ϯ3% by Ba 2ϩ plus ouabain) because, due to concerns related to toxicity, we did not perform prolonged infusions. Vasoconstriction caused by Ba 2ϩ may therefore not have reached a plateau. Even so, Ba 2ϩ -induced vasoconstriction was substantial and compares with a maximum vasoconstrictor effect of L-N G -monomethyl-L-arginine (which blocks basal endothelium-derived nitric oxide synthesis in this vascular bed) of Ϸ50% reduction of basal blood flow. 29 Another limitation of the study is that it was not practicable to investigate the effect of Ba 2ϩ on K ϩ -induced responses throughout a dose range of KCl infusions because responses to lower doses of KCl were small and variable and larger doses could not be used as these caused forearm discomfort.
Tonic vasodilator activity of K ϩ within the physiological range could influence arterial blood pressure. Dietary supplementation with potassium salts has been reported to lower blood pressure in patients with essential hypertension. 30, 31 Conversely, elevated blood pressure has been described in association with low dietary K ϩ . 32 The ability of a small increase in [ Absolute forearm blood flow (meanϮSEM) in response to brachial artery infusions of vasodilators comprising KCl (0.2 mmol/min; nϭ6) or nitroprusside (NP) (3.6 nmol/min; nϭ4). Each vasodilator was studied on a separate occasion. Vasodilators were infused alone, and with a coinfusion of ouabain (2.7 nmol/min) and BaCl 2 (4 mol/min).
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Actions of Ba 2؉ on Human Forearm Blood Flowachieved in venous blood draining the infused arm are in the range observed in voluntary muscle during exercise, 4 supporting a role for K IR and for Na ϩ /K ϩ ATPase activation in regional blood flow responses during exercise. 4 It is likely that mechanisms similar to those we have observed in forearm vasculature also operate in vivo in cerebral and coronary vessels (which are perfused by plasma of the same composition as are forearm vessels) and in which K IRchannels have been detected in vitro. 2, 3 If so, K ϩ -induced vasodilation could be important in pathological conditions such as myocardial or cerebral infarction, in which local elevations of [K ϩ ] o could reduce resistance vessel tone in and around the infarct. 4 Furthermore, hyperpolarization-induced vasorelaxation by activation of Na ϩ /K ϩ ATPase is reported to be upregulated when nitric oxide bioavailability is impaired, 33 ,34 so K ϩ -induced vasodilation could provide a compensatory mechanism in diseases in which the L-arginine/ nitric oxide mechanism is impaired, especially if the K IR mechanism also proves to be upregulated in such disorders.
In conclusion, Ba 2ϩ constricts forearm resistance vessels, and K ϩ -induced vasodilation is selectively inhibited by Ba and almost abolished by Ba 2ϩ plus ouabain. These findings support a role for K IR and Na ϩ /K ϩ ATPase in controlling basal tone and in K ϩ -induced vasorelaxation in human forearm resistance vessels in vivo. Such a role has important implications for the (patho-) physiological regulation of resistance vessel tone in humans.
